MCL1/CDK9 screen published in eLife

Our CRISPR screening projects are starting to come out! Today work from postdoc Shaheen Kabir, in collaboration with oncologists at AstraZeneca, was published in eLife. Shaheen used a very creative FACS screen to find genes involved in the early apoptotic response to CDK9 and MCL1 inhibitors. Inhibition of CDK9 reduces transcript half-life and indirectly inhibits MCL1, whereas the other compound screen directly binds MCL1. Several cancers respond well to these new compounds, but others are already completely resistant. Shaheen went looking for genes involved in this resistance and found some very interesting shared hits. She focused her mechanistic work on the CUL5 ubiquitin ligase complex, which is a multi-component system used to degrade target proteins. Almost every component of the CUL5 complex was a hit in the screen, and Shaheen found that knockdown of CUL5 components affected the stability of pro-apoptotic proteins Bim and Noxa. CUL3 type ligases are already established cancer targets, and Shaheen’s work shows that CUL5 could also be targeted to synergize with front-line cancer therapeutics. Congratulations Shaheen!

SUBMIT A COMMENT

Your email address will not be published. Required fields are marked *

Filters

Latest News

June 23, 2025

SWISSPR 2025

SWISSPR 2025, hosted by the Corn, Platt, Schwank, and Jinek labs, was a fantastic retreat that brought together cutting-edge CRISPR research at Seminarhotel...

May 12, 2025

Welcome to Dora!

Dora obtained her Master’s degree in Chemistry from ETH Zurich in 2019, where she conducted research on the Synthesis of trypanothione reductase inhibitors...

April 22, 2025

Welcome back to Dominic!

Dominic Mailänder received his Master’s degree in Molecular Health Sciences from ETH Zurich in 2024. Dominic returned to the Corn Lab as a Research ...

News Archive

Tweets